Pharmaceuticals APAC

APAC Travel Vaccines Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

APAC Travel Vaccines Market Industry Trends and Forecast to 2034: Segmented by (Disease, Channel, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

APAC · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $883.2 Mn Placeholder estimate
Estimate 2025 $952.9 Mn 20.8% of the global market
Projected 2034 $1.89 Bn 98.2% Adds $936.2 Mn over 9 forecast years
CAGR 2025–2034 7.9% Faster than 31% of 180 Pharmaceuticals markets here
Key players 5
  • APAC is 20.81% of the global market.
  • Among regions, the largest is North America at $2.36 Bn.
  • Fastest growing: Africa at 8.6% a year.
  • APAC ranks 2nd of 6 by size among regions.

Market size projection

APAC

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$936.2 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Travel Vaccines Market market size by year, APAC
YearMarket sizeChange that yearSince 2025
2024 (estimate) $883.2 Mn — —
2025 (base) $952.9 Mn +$69.8 Mn —
2026 (forecast) $1.03 Bn +$75.3 Mn +7.9%
2027 (forecast) $1.11 Bn +$81.2 Mn +16.4%
2028 (forecast) $1.20 Bn +$87.6 Mn +25.6%
2029 (forecast) $1.29 Bn +$94.6 Mn +35.5%
2030 (forecast) $1.39 Bn +$102.0 Mn +46.3%
2031 (forecast) $1.50 Bn +$110.1 Mn +57.8%
2032 (forecast) $1.62 Bn +$118.8 Mn +70.3%
2033 (forecast) $1.75 Bn +$128.2 Mn +83.7%
2034 (forecast) $1.89 Bn +$138.3 Mn +98.2%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

APAC Travel Vaccines Market Analysis at a glance
Market size, 2025$952.9 Mn placeholder estimate
Forecast, 2034$1.89 Bn placeholder estimate
Growth (CAGR), 2025–20347.9% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDisease, channel and end user (see all)
Key playersSanofi, Valneva, Bavarian Nordic, GSK PLC, Bharat Biotech (see all)
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The APAC Travel Vaccines Market Analysis Executive Summary

Travel vaccines protect travellers against diseases common in other regions, such as typhoid, yellow fever, rabies and cholera.

Key segments of the travel Vaccines market include disease (Typhoid, Yellow Fever and Rabies) and channel (Travel Clinics, Pharmacies and Hospitals).

Bar chart: Asia Pacific Travel Vaccines market size, 2024–2034, placeholder estimates. $883.2 Mn in 2024, $952.9 Mn in 2025 and $1.89 Bn in 2034, 7.9% CAGR.
Asia Pacific Travel Vaccines market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

APAC Travel Vaccines Market Dynamics

Market Growth Drivers

Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the travel Vaccines market.

Opportunity

New vaccines, rapid tests and public-private funding for neglected diseases give the travel Vaccines market room to grow, especially in Asia, Africa and Latin America.

Market Restraints

Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the travel Vaccines market.

Competitive Landscape for Travel Vaccines Market in APAC

The travel Vaccines market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Travel Vaccines Market in APAC

Travel Vaccines in APAC: rules and payment

In some of the countries we cover here, medicines are approved by TGA (Australia)⁠[1], NMPA (China)⁠[2], Drug Office (Hong Kong)⁠[3], CDSCO (India)⁠[4], PMDA (Japan)⁠[5], NPRA (Malaysia)⁠[6], Medsafe (New Zealand)⁠[7], FDA Philippines (Philippines)⁠[8], HSA (Singapore)⁠[9] and Thai FDA (Thailand)⁠[10]. How care is paid for in some of these countries: Medicare and the PBS (Australia)⁠[11], basic medical insurance (China)⁠[12], the Hospital Authority (Hong Kong)⁠[13], Ayushman Bharat PM-JAY (India)⁠[14], public health insurance (Japan)⁠[15], subsidised public care (Malaysia)⁠[16], Pharmac (New Zealand)⁠[17], PhilHealth (Philippines)⁠[18], MediShield Life (Singapore)⁠[19] and the Universal Coverage Scheme (Thailand)⁠[20].

[1] Therapeutic Goods Administration. Checked 14 Nov 2026.

[2] National Medical Products Administration. Checked 14 Nov 2026.

[3] Drug Office, Department of Health. Checked 14 Nov 2026.

[4] Central Drugs Standard Control Organisation. Checked 14 Nov 2026.

[5] Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.

[6] National Pharmaceutical Regulatory Agency. Checked 14 Nov 2026.

[7] Medsafe. Checked 14 Nov 2026.

[8] Food and Drug Administration Philippines. Checked 14 Nov 2026.

[9] Health Sciences Authority. Checked 14 Nov 2026.

[10] Thai Food and Drug Administration. Checked 14 Nov 2026.

[11] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.

[12] National Healthcare Security Administration. Checked 14 Nov 2026.

[13] Hospital Authority. Checked 14 Nov 2026.

[14] National Health Authority (PM-JAY). Checked 14 Nov 2026.

[15] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.

[16] Ministry of Health Malaysia. Checked 14 Nov 2026.

[17] Pharmac. Checked 14 Nov 2026.

[18] PhilHealth. Checked 14 Nov 2026.

[19] CPF Board, MediShield Life. Checked 14 Nov 2026.

[20] National Health Security Office. Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for travel Vaccines. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in APAC.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Travel Vaccines right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Travel Vaccines in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Travel Vaccines market in Asia Pacific?
Placeholder estimate: about $952.9 Mn in 2025, rising to about $1.89 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Travel Vaccines market in Asia Pacific growing?
Placeholder estimate: about 7.9% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Travel Vaccines market report cover?
The report splits the market by disease (Typhoid, Yellow Fever, Rabies, Japanese Encephalitis and more), channel (Travel Clinics, Pharmacies, Hospitals) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Travel Vaccines market?
Key players include Sanofi, Valneva, Bavarian Nordic, GSK PLC and Bharat Biotech.
What is driving the Travel Vaccines market?
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the travel Vaccines market.
How much research is published on Travel Vaccines?
PubMed lists 27 papers on Travel Vaccines added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in APAC

See all

Related on vaccines and infectious diseases

See the topic